Fulvestrant in Hormone-refractory Prostate Cancer
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have a rising serum prostate specific antigen (PSA).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Fulvestrant
Phase: Phase 2
Ages Eligible For Study:
- Must give signed written informed consent - Must be of age 18 years or older - Histologically confirmed adenocarcinoma of the prostate - Must be currently receiving LHRH agonists and have castrate levels of testosterone or have had an orchiectomy - Must have had rise in PSA despite anti-androgen withdrawal - Must exhibit two consecutive rises in PSA after the last hormonal manipulation - Minimum PSA > 5mg/dL - KPS > 80% - Up to one prior chemotherapy treatments allowed - Life expectancy of greater than 6 months